Valby – October 02, 2026 -- H. Lundbeck A/S will present late-breaking Phase III data on its multiple system atrophy (MSA) drug candidate amlenetug alongside new Parkinson's disease pipeline results at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, running October 4-8.
MASCOT trial enrolled 401 participants across a global Phase III program
The late-breaking oral presentation will detail baseline characteristics of participants in MASCOT (NCT06706622), Lundbeck's ongoing Phase III trial of amlenetug in MSA. The trial enrolled 401 participants with clinically probable or established MSA, covering both MSA-C and MSA-P subtypes, across sites in North America, Europe, Asia and Australia. The double-blind treatment period runs 72 weeks, comparing high- and low-dose amlenetug against placebo, with results expected in Q3 2027.
US cost data shows MSA care burden exceeds Parkinson's disease
A US observational database study presented at the congress found significantly higher healthcare costs and resource utilization among MSA patients compared with Parkinson's disease patients. Lundbeck is also presenting validation data for the modified UMSARS Part I as a clinical trial endpoint, a Chinese-language validation of UMSARS, and cerebrospinal fluid biomarker research aimed at improving MSA detection and differential diagnosis.
Phase Ib data targets dopamine agonist for advanced Parkinson's motor complications
Lundbeck will present new Phase Ib data for Lu AF28996, an oral D1-like/D2-like dopamine receptor agonist prodrug. The 18-week open-label trial assessed safety, tolerability and clinical effects in patients with inadequately controlled advanced Parkinson's disease experiencing motor fluctuations, with or without dyskinesia. The clinical data will be paired with preclinical findings from an MPTP-macaque primate model examining the relationship between dose, motor efficacy and dyskinesia. Lu AF28996 has advanced into Phase II development through the DARE2 trial (NCT07514858).
Executive cites expanding scientific commitment to movement disorders
"Movement disorders such as MSA and Parkinson's disease remain among the most complex and high-need areas in neuroscience," said Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck. Amlenetug, a human monoclonal antibody targeting extracellular alpha-synuclein, is being developed under a joint research and licensing agreement between Lundbeck and Genmab A/S. Both amlenetug and Lu AF28996 remain investigational and have not been approved by any regulatory authority.